REFERENCES
1 Griffith DE, Eagle G, Thomson R, et al. Amikacin Liposome Inhalation
Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium
avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am
J Respir Crit Care Med 198(12): 1559-1569, 2018.
2 Swenson C, Lapinel NC, Ali J. Clinical Management of Respiratory
Adverse Events Associated With Amikacin Liposome Inhalation Suspension:
Results From a Patient Survey. Open Forum Infect Dis 7(4): ofaa079,
2020.